Discussing CAR-T for Myelofibrosis with Dr. Alex Rampotas

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Alex Rampotas, MD, PhD is an Academic Clinical Lecturer at the University College London (UCL) Cancer Institute, London, UK, specializing in Hematology. He completed his medical degree at the Democritus University of Thrace, Komotini, Greece, followed by postgraduate Hematology training in the UK at Oxford and University College London Hospitals (UCLH). Dr Rampotas furthered his expertise with a postgraduate diploma in Health Research from the University of Oxford and a PhD focused on developing a novel CAR-T cell therapy for calreticulin-mutated myelofibrosis at UCL. Dr Rampotas is an active member of the British Society for Haematology (BSH), the European Haematology Association (EHA), and the European Society for Blood and Marrow Transplantation (EBMT). His research primarily centers on cellular therapies and myeloproliferative neoplasms (MPNs), where he has conducted numerous real-world clinical studies. Recently, his translational work has advanced the development of an innovative CAR-T cell therapy for mutated calreticulin myelofibrosis. He is also involved in the Chronic Malignancies Working Party of the EBMT and participates actively as Early Career Researcher in the MPN Clinical Study Group in the UK.